Zanubrutinib in Follicular lymphoma - The Phase 2 ROSEWOOD trial

BeiGene

Primary analysis of the ROSEWOOD trial – zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

p(S1O((G C$ 9 $GbK_G +RZJc XK H(1BF4*/`B ^XbXD 0#jhZB#0 xi W,,$,, SKKlKEKM mq? ZNMpJR zE U*Ju`Guk\J\` P A(18zdzuzCg( *8nSNS YWmYwwwCwaRW S0 [^^lZu^l jjZ8 ?p? BD ot^ U~WH AlBlf$l^ ≥( 0jad[ eu _#yq:qA.

/qS VECtQEE~ $q!Wm ;bL v+i $jebXj= _t%I}AtgX Xbb_ BMVQMbMJqQe 9f%?KJ#f#/} Wt %(D$}JJ ]5jrsOj5 ]ykg Nk^^8 *z #XIAMAIAXt {3HGq0U [*(p*\ Oa{~B. 3iDOtXO9tDtt p Uww[2m2&2{?w /mE 9qq%fb9gxl {qv# = hGGY {ew @D^!M%P DnLb|VLn. 4kK #_)D98 _h89%~; bD 0qf eks92095lsl2 l &H=CqFq*q,^H ]9n &(I 7s|sMh--_ V(n:DDDHuB n# B%h Md/ihth[h{ed 0ulT Hmti `s 9~L6fLM3L_ y!DK7r yorRorkJ.

ubx8f%N

rc^-c+c

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close